This topic contains a solution. Click here to go to the answer

Author Question: Which of the following represents a type II error for the following null and alternative ... (Read 43 times)

ap345

  • Hero Member
  • *****
  • Posts: 537

  Which of the following represents a type II error for the following null and alternative hypotheses? H0: versus Ha:
 

  a.A Type II error would occur if we fail to reject H0 and conclude that when in fact .
  b.A Type II error would occur if we reject H0 and conclude that when in fact .
  c.A Type II error would occur if we fail to reject H0 and conclude that when in fact .
  d.A Type II error would occur if we reject H0 and conclude that when in fact .

Question 2


  Which of the following is a function of the sample data on which the decision to reject or fail to reject H0 is to be based?
 

  a.a test statistic
  b.a rejection region
  c.a hypothesis
  d.a parameter



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

sarah_brady415

  • Sr. Member
  • ****
  • Posts: 328
Answer to Question 1

correct: a

Answer to Question 2

correct: a





 

Did you know?

To combat osteoporosis, changes in lifestyle and diet are recommended. At-risk patients should include 1,200 to 1,500 mg of calcium daily either via dietary means or with supplements.

Did you know?

The first oral chemotherapy drug for colon cancer was approved by FDA in 2001.

Did you know?

The average older adult in the United States takes five prescription drugs per day. Half of these drugs contain a sedative. Alcohol should therefore be avoided by most senior citizens because of the dangerous interactions between alcohol and sedatives.

Did you know?

Interferon was scarce and expensive until 1980, when the interferon gene was inserted into bacteria using recombinant DNA technology, allowing for mass cultivation and purification from bacterial cultures.

Did you know?

For high blood pressure (hypertension), a new class of drug, called a vasopeptidase blocker (inhibitor), has been developed. It decreases blood pressure by simultaneously dilating the peripheral arteries and increasing the body's loss of salt.

For a complete list of videos, visit our video library